Ads
related to: biotech stocks with phase 3 trials
Search results
The 3 Best Biotech Stocks to Buy in June 2024
InvestorPlace· 17 hours agoDespite these challenges, some of the best biotech stocks show promise and resilience in a volatile market environment. This is a boon for investors who...
June's Biotech Boom: 3 Stocks to Buy for a Summertime Surge
InvestorPlace· 1 day agoBiotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the...
Medical Moonshots: 3 Biotech Stocks Set to Skyrocket
InvestorPlace· 7 days agoThanks to biotech companies that produce transformative drugs and treatments, we now have the collective ability to combat diseases that used to bring...
Cathie Wood Is Buying the Dip on These 2 Biotech Stocks. Should You?
Motley Fool via Yahoo Finance· 2 days agoJust be aware that this stock could be volatile in the meantime, depending on what breakthroughs (or...
Piper Sandler initiates coverage of biotech stocks By Investing.com
Investing.com· 6 days agoPiper Sandler initiated coverage of several biotech stocks in a note Friday, with all, barring one,...
3 Sorry Biotech Stocks to Sell in May While You Still Can
InvestorPlace· 6 days agoMorgan Stanley recently released its bullish take on the biotech space, driven by anticipated...
Citi maintains 'Buy' on Arcus Biosciences stock, cites promising trial results By Investing.com
Investing.com· 3 days agoThis adjustment follows the promising results from the EDGE...outcome was consistent across both...
1 Disruptive Biotech Stock to Buy Now, and 1 to Consider
Motley Fool via Yahoo Finance· 3 days ago*Stock Advisor returns as of June 3, 2024 Alex Carchidi has no position in any of the stocks...
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
Motley Fool via Yahoo Finance· 3 days agoTherefore, the stock is not yet worth buying on the basis of the company...ambitious plan for 2030,...
Crinetics shares maintain price target, Overweight rating on positive trial data By Investing.com
Investing.com· 2 days ago(NASDAQ:CRNX), following the presentation of encouraging trial data. The company, at the ENDO 2024...
